A Novel Full-Length Recombinant Human Complement Factor H (CFH; GEM103) for the Treatment of Age-Related Macular Degeneration Shows Similar <i>In Vitro</i> Functional Activity to Native CFH.

Biggs, Robyn M; Makou, Elisavet; Lauder, Scott; Herbert, Andrew P; Barlow, Paul N; Katti, Suresh K

A Novel Full-Length Recombinant Human Complement Factor H (CFH; GEM103) for the Treatment of Age-Related Macular Degeneration Shows Similar In Vitro Functional Activity to Native CFH.

Biggs, Robyn M; Makou, Elisavet; Lauder, Scott; Herbert, Andrew P; Barlow, Paul N; Katti, Suresh K.

Afiliação

Biggs RM; Gemini Therapeutics Inc., Cambridge, MA, USA.
Makou E; School of Chemistry, University of Edinburgh, Edinburgh, UK.
Lauder S; Gemini Therapeutics Inc., Cambridge, MA, USA.
Herbert AP; School of Chemistry, University of Edinburgh, Edinburgh, UK.
Barlow PN; School of Chemistry, University of Edinburgh, Edinburgh, UK.
Katti SK; School of Biological Sciences, University of Edinburgh, Edinburgh, UK.

Curr Eye Res ; 47(7): 1087-1093, 2022 07.

Article em En | MEDLINE | ID: mdl-35282732

Assuntos

Fator H do Complemento; Degeneração Macular; Animais; Fator H do Complemento/genética; Fator H do Complemento/metabolismo; Hemólise; Humanos; Degeneração Macular/tratamento farmacológico; Degeneração Macular/genética; Degeneração Macular/metabolismo; Polimorfismo de Nucleotídeo Único; Ovinos

Palavras-chave

GEM103; age-related macular degeneration; alternative pathway; complement factor H; recombinant protein therapy

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Fator H do Complemento / Degeneração Macular Limite: Animals / Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google